TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05293587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
Study: NCT04949867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop System
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Closed-loop System
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
Study: NCT06020105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NURLIFE
Description: After the first consultation with the surgeon, the patients will be referred to the case manager, who will carry out the first face-to-face consultation, with consequent monitoring and clarification of identified needs, following the flowchart in figure 3, being referred to the different specialties, psychology, nutrition and nursing, fostering the case manager as the central pillar of the process, which will monitor each process individually, namely the number of consultations and necessary referrals.
Study: NCT05903599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: The size of both electrodes will be 5cm x 5cm placed on the head with the anode on the primary motor cortex M1 of the affected side while the cathode on the contralesional eye. The duration of the stimulation of anodal TDCS is 20 min and the intensity of current will be 2mA. The ramp up and down period will be 30se each. Treatment duration will be 5 times a week for 6 weeks for postural stability.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: postural training by visual feedback and weight shifting towards the non-paretic side. This program will have two phases. Phase one have 4 stages; The first stage (sessions 1-7), second stage (sessions 8-14), third stage (sessions 15-22), fourth stage (sessions 23-30).~Next phase will include the exercises including balancing exercises.
Study: NCT06297499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: administration of an IV solution of 8mg ondansetron (4ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: administration of an IV solution of 8mg ondansetron (4ml)
Study: NCT04885881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection group
Description: Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
Study: NCT06267547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAIL Online Platform
Description: The HAIL online platform was developed based on feedback from our focus groups with older adults affiliated with BMA churches (conducted per IRB Protocol 2020P003100). Specifically, the HAIL online platform has a landing page where participants can access the links to the F\&S! exercise sessions, complete the exercise log, obtain tips from an exercise instructor, as well as view study announcements. The landing page has a navigation bar on the left to access 1) the study assessments; 2) the F\&S! exercise program participant manual; and 3) information on how to contact study staff. The goal of this adjunctive HAIL online platform is to support the continuation of exercise in the follow-up period once the 8-week F\&S! exercise program is over. We conducted an open trial (per IRB protocol 2022P001782) to assess the feasibility and acceptability of the HAIL online platform adjunct to the F\&S! program, which yielded positive results.
Study: NCT05541003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBT-NM108
Description: All patients will consume NBT-NM108 in the form of 2 muffins daily.
Study: NCT05885763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difelikefalin Injection
Description: Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study: NCT04817124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
Study: NCT06117839

Intervention type: PROCEDURE
Intervention: using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.
Description: -There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .

Intervention type: PROCEDURE
Intervention: using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.
Description: -There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .
Study: NCT04846712

Intervention type: OTHER
Intervention: Collect data of medical record
Description: Collect data of medical record: initial physical examination, ultrasound (US), Magnetic Resonance Imaging (MRI), physical examination at 30 days, physical examination at 3 months, physical examination at 6 months and final examination at 12 months.
Study: NCT05537142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion
Study: NCT06526793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.
Study: NCT05395026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation of vagus nerve
Description: VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
Study: NCT06267547

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fit and Strong! Program
Description: The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong! Program
Description: The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
Study: NCT06529393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SHAC block
Description: with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, the investigators also reach the intra-articular space .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block
Description: Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
Study: NCT05400837

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Corrie Virtual Atrial Fibrillation Management Program
Description: Intervention aims to implement guideline-recommended Afib care
Study: NCT06530563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine Injection [Olinvyk]
Description: Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oliceridine Injection [Olinvyk]
Description: Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Citrate
Description: Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Citrate
Description: Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.
Study: NCT06527495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib Tablets (200 -400 mg) twice daily
Study: NCT05910710

Intervention type: GENETIC
Intervention: Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Description: Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation

Intervention type: GENETIC
Intervention: Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Description: Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
Study: NCT06391905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor in combination with standard advanced first-line regimen group
Description: Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment

Intervention type: DRUG
Group type: OTHER
Intervention: standard advanced first-line regimen group
Description: Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
Study: NCT05703555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine
Description: Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
Study: NCT05928728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT05447585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary atherectomy system of Shanghai MicroPort Rhythm
Description: Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotablator Rotational Atherectomy System
Description: The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
Study: NCT06463938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: CPP-ACP paste will be applied on exposed area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Lasotronix will be applied following its protocol

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Combination of laser and paste
Description: This group will receive the combination of above two treatments

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: this will be a control group
Study: NCT04977427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
Study: NCT04676022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveWriter
Description: To receive Spinal Cord Stimulation programming
Study: NCT05561673

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide
Description: Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system
Description: Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
Description: Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1
Description: Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
Study: NCT04676022

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Medical Managament
Description: To receive conventional medical management
Study: NCT06357728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
Study: NCT05677763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85
Description: Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85
Description: Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered Placebo once daily. (10 days per month)
Study: NCT06009458

Intervention type: DEVICE
Group type: OTHER
Intervention: Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Description: Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
Study: NCT05630235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/CBD-A
Description: Participants will be administered a one-time dose of 217.7 mg of CBD/CBD-A orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/CBD-A
Description: Participants will be administered a one-time dose of 217.7 mg of CBD/CBD-A orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo equivalent of the CBD/CBD-A dose administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo equivalent of the CBD/CBD-A dose administered orally.
Study: NCT06635902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
Study: NCT06636214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHATO-I
Description: Online communication education program
Study: NCT05687656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnovaMatrix AC porcine placental ECM therapy
Description: All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
Study: NCT06318481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 MG
Description: Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
Study: NCT05321810

Intervention type: DRUG
Intervention: Apixaban
Description: This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.

Intervention type: DRUG
Intervention: Warfarin
Description: This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
Study: NCT05127603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Description: Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
Study: NCT06541392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast 6.30 am
Description: This group will have breakfast time from 6.30 to 7.30 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast 7.31 am
Description: This group will have breakfast time from 7.31 to 8.31 am
Study: NCT06047158

Intervention type: DRUG
Intervention: Omega-3 fish oil fat emulsion
Description: Use omega-3 fish oil fat emulsion
Study: NCT05425108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Binocular CP1
Description: Binocular active projection of defocused image in the peripheral visual field